CRISPR Therapeutics (NASDAQ:CRSP) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) to a sell rating in a research note released on Thursday.

A number of other research analysts have also issued reports on CRSP. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Wednesday. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $74.05.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $43.49 on Thursday. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The company’s fifty day moving average price is $42.06 and its two-hundred day moving average price is $46.25. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.37 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, sell-side analysts anticipate that CRISPR Therapeutics will post -5.08 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of the business. Sanctuary Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at $381,000. Exchange Traded Concepts LLC raised its stake in shares of CRISPR Therapeutics by 22.8% in the third quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock worth $902,000 after acquiring an additional 3,563 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in shares of CRISPR Therapeutics by 3.7% in the third quarter. Vontobel Holding Ltd. now owns 16,957 shares of the company’s stock valued at $797,000 after purchasing an additional 600 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in CRISPR Therapeutics by 56.4% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 13,617 shares of the company’s stock worth $640,000 after purchasing an additional 4,909 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of CRISPR Therapeutics during the third quarter worth $258,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.